...
首页> 外文期刊>Italian journal of pediatrics >Efficacy of Grintuss? pediatric syrup in treating cough in children: a randomized, multicenter, double blind, placebo-controlled clinical trial
【24h】

Efficacy of Grintuss? pediatric syrup in treating cough in children: a randomized, multicenter, double blind, placebo-controlled clinical trial

机译:格林特斯的功效?小儿糖浆治疗儿童咳嗽:一项随机,多中心,双盲,安慰剂对照的临床试验

获取原文

摘要

Background Cough is an extremely common problem in pediatrics, mostly triggered and perpetuated by inflammatory processes or mechanical irritation leading to viscous mucous production and increased sensitivity of the cough receptors. Protecting the mucosa might be very useful in limiting the contact with micro-organisms and irritants thus decreasing the inflammation and mucus production. Natural molecular complexes can act as a mechanical barrier limiting cough stimuli with a non pharmacological approach but with an indirect anti-inflammatory action. Objective Aim of the study was to assess the efficacy of a medical device containing natural functional components in the treatment of cough persisting more than 7?days. Methods In this randomized, parallel groups, double-blind vs. placebo study, children with cough persisting more than 7?days were enrolled. The clinical efficacy of the study product was assessed evaluating changes in day- and night-time cough scores after 4 and 8?days (t4 and t8) of product administration. Results In the inter-group analysis, in the study product group compared with the placebo group, a significant difference (t4 study treatment vs. t4 placebo, p?=?0.03) was observed at t4 in night-time cough score. Considering the intra-group analysis, only the study product group registered a significant improvement from t0 to t4 in both day-time (t0 vs. t4, p?=?0.04) and night-time (t0 vs. t4, p?=?0.003) cough scores. A significant difference, considering the study product, was also found in the following intra-group analyses: day-time scores at t4 vs. t8 (p =0.01) and at t0 vs. t8 (p?=?0.001); night-time scores at t4 vs. t8 (p?=?0.05), and at t0 vs. t8 (p?=?0.005). Considering a subgroup of patients with higher cough (≥3) scores, 92.9% of them in the study product group improved at t0 vs. t4 day-time. Conclusions Grintuss? pediatric syrup showed to possess an interesting profile of efficacy and safety in the treatment of cough persisting more than 7?days.
机译:背景技术咳嗽是小儿科的一个非常普遍的问题,主要是由炎症过程或机械刺激引起并长期存在,导致粘液产生和咳嗽受体敏感性增加。保护粘膜在限制与微生物和刺激物的接触从而减少炎症和粘液产生方面可能非常有用。天然分子复合物可通过非药理学方法充当机械性屏障,限制咳嗽刺激,但具有间接的抗炎作用。目的本研究的目的是评估含有天然功能成分的医疗器械治疗持续7天以上的咳嗽的疗效。方法在这项随机,平行分组,双盲与安慰剂研究中,纳入咳嗽持续超过7天的儿童。评估研究产品的临床疗效,评估在给药4天和8天(t4和t8)后白天和夜间咳嗽评分的变化。结果在组间分析中,研究产品组与安慰剂组相比,夜间咳嗽评分在t4时观察到显着差异(t4研究治疗组与t4安慰剂组,p≥0.03)。考虑到组内分析,只有研究产品组在白天(t0 vs. t4,p?=?0.04)和夜间(t0 vs. t4,p?=)从t0到t4都有显着改善。 0.003)咳嗽分数。考虑到研究结果,在以下组内分析中也发现了显着差异:t4 vs. t8(p = 0.01)和t0 vs. t8(p?=?0.001)的日间成绩;在t4对比t8的夜间得分(p?=?0.05),以及在t0对比t8的夜间得分(p?=?0.005)。考虑到咳嗽评分较高(≥3)的亚组患者,研究产品组中92.9%的患者在白天t0和t4时有所改善。结论格林图斯?小儿糖浆在治疗持续7天以上的咳嗽方面显示出有趣的功效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号